Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
TR
By Tom Reyes · Markets Editor
Nov 7 10:03 ETSource: Yahoo! Finance Canada
From the source
Read at ca.finance.yahoo.comJohnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
